ABOUT US

The UCL Division of Surgery and Interventional Science is a collaborative and cross-disciplinary environment where clinicians, engineers, allied health professionals and researchers are constantly striving for innovative approaches to treatment.
As a world leader in medical and biomedical research we are able to see at first-hand the directions in which medicine and science are moving and where patient and industry needs are growing. This knowledge ensures that we are producing and teaching some of the most innovative courses for clinicians and scientists across the world. Additionally, our cutting-edge research expertise ensures that the latest techniques are taught using the most advanced equipment. Finally, we offer innovative courses led by world leading experts, providing a truly research-based learning experience delivered by some of the greatest minds in science and medicine today.
The Division reaching across three London campuses (Bloomsbury, Royal Free and Stanmore) brings together three major research departments; Tissue and Energy, Nanotechnology and Materials and Tissue. Within these departments are world class research centres, specialising in many different surgical and interventional specialties.

ABOUT THE ROLE

The Prostate Cancer Unit at UCL has carried out unprecedented work over the years, transforming our understanding of this disease and the global approaches to diagnosing and treating it. Founded by Professor Mark Emberton, UCL prostate cancer researchers discovered the benefits of using magnetic resonance imaging (MRI) scanners for prostate cancer diagnosis. Proved to be efficient and non-invasive, this discovery has doubled the accuracy of prostate cancer diagnosis, allowing thousands of men a year to avoid an unnecessary biopsy. Few institutions have the expertise, history of success and specialist infrastructure to carry out the pioneering research and clinical trials needed to drive forward research in prostate cancer today. At UCL we are world leader in prostate MRI and two key studies of the last 10 years (PROMIS, PRECISION and PRIME trials) have been successfully led by our group of researchers and clinicians.
This job is ideal for a pre-CCT doctor in training or returning to training after the research post. Post-CCT doctors are welcome to apply but it would be funded pro rata as per their consultant salary scale and be dependent on undertaking joint employment as per the Follett principles.

Other

• The advert will close on 12 October 2025 at 23:59 GMT, however we may close applications early if we receive a high volume of applications. Early application submission is recommended.
• Interview Date(s) TBC
• If you have any queries about the role, please contact Veeru Kasivisvanathan on veeru.kasi@ucl.ac.uk
• If you need reasonable adjustments or a more accessible format to apply for this job online or have any queries about the application process, please contact the HR Team on l.oppong@ucl.ac.uk
• The UCL Ways of Working supports colleagues to be successful and happy at UCL through sharing expectations around how we work – please visit www.ucl.ac.uk/ways-of-working to find out more.

Closing an advert early: In the event we get a high number of applications, we may close the advert early before the published closing date. As a minimum we will keep all adverts open for 2 weeks.

As well as the exciting opportunities this role presents, we also offer some great benefits some of which are below:

• 41 Days holiday (27 days annual leave 8 bank holiday and 6 closure days)
• Additional 5 days’ annual leave purchase scheme
• Defined benefit career average revalued earnings pension scheme (CARE)
• Cycle to work scheme and season ticket loan
• Immigration loan
• Relocation scheme for certain posts
• On-Site nursery
• On-site gym
• Enhanced maternity, paternity and adoption pay
• Employee assistance programme: Staff Support Service
• Discounted medical insuranc